Database of all ivermectin COVID-19 studies. 93 studies, 54 peer reviewed, 56 with results comparing treatment and control groups. Submit updates/corrections below. FLCCC provides treatment recommendations.

5/18	In Vit <i>Mountain Vall. in vitro</i> Mountain Valley MD Receives Successful Re <i>In Vitro</i> and mouse study with human ACE2 cells, using solubilized ivermectin with Ivectosol™, sho
5/18	Early, <i>Covid Analysis</i> meta-analysis v83 Ivermectin for COVID-19: real-time meta anal • 97% of 37 early treatment and prophylaxis studies report positive effects (95% of all 56 studies)
5/12	News FLCCC Public news FLCCC Alliance Statement on the Irregular A Analysis of the ivermectin recommendations from WHO and others, and a call to action for all citiz
5/10	Early <i>Faisal</i> et al., <i>Th</i> no recov., \$\diamonds 68.4% Potential use of azithromycin alone and in c RCT 100 outpatients in Pakistan, 50 treated with ivermectin, showing faster recovery with ivermec
5/5	In Vit Zatloukal et al news News report on In Vitro results from the rese News report on In Vitro results from the research institute of Prof. Zatloukal, showing that "iverme
5/5	In Sili <i>Qureshi</i> et al., <i>Journal of Biomolecular</i> Mechanistic insights into the inhibitory activi In Silico study showing inhibition of importin-α1 by ivermectin, which disrupts SARS-CoV-2 replicat
5/4	Meta <i>Karale</i> et al., m meta-analysis A Meta-analysis of Mortality, Need for ICU a Systematic review and meta analysis with 30 studies included in quantitative analysis, showing m
5/3	Early <i>Merino</i> et al., S hosp., \74.4%, p< Ivermectin and the odds of hospitalization d Analysis of Mexico City's use of an ivermectin-based medical kit, showing significantly lower hospi
4/30	Revi Kory et al., Am review Review of the Emerging Evidence Demonstr Review of ivermectin trials and epidemiological data, concluding that ivermectin is effective for pr
4/19	Revi DiNicolantonio review Anti-inflammatory activity of ivermectin in lat Review suggesting that the effectiveness of ivermectin in the cytokine storm phase of COVID-19
4/17	Early Loue et al., J. I death, \$\psi\$70.0%, p Ivermectin and COVID-19 in Care Home: Cas Small quasi-randomized (patient choice) study with 25 PCR+ patients in a nursing home offered iv
4/16	PrEP Morgenstern e hosp., ↓80.0%, p= Retrospective cohort study of Ivermectin as

https://c19ivermectin.com 1/11

	Propensity matched retrospective prophylaxis study of healthcare workers in the Dominican Repu
4/14	PrEP Seet et al., Inte severe case, ↓49 Positive impact of oral hydroxychloroquine a Prophylaxis RCT in Singapore with 3,037 low risk patients, showing lower serious cases, lower sy
4/10	In Sili Bello et al., Journal of Biomolecular St Elucidation of the inhibitory activity of iverm In Silico analysis finding that the in vitro activity of ivermectin may explained by acting as an inhibit
4/3	Revi <i>Turkia, M., Res</i> review A timeline of ivermectin-related events in the An extensive timeline of ivermectin-related events from April 2020 to March 2021 including studie
4/1	Early <i>Mourya et al., I</i> viral+, \$89.4%, p< Comparative Analytical Study of Two Differe Retrospective 100 patients in India with 50 treated with ivermectin, and SOC for all patients includi
3/30	Revi Wehbe et al., F review Repurposing Ivermectin for COVID-19: Molec Review of how ivermectin was identified for use in COVID-19, mechanisms of action, and selected
3/30	Early <i>Chahla et al., R</i> no disch., ↓86.9% Cluster Randomised Trials - Ivermectin Repu Cluster RCT outpatients in Argentina showing signficantly faster recovery with ivermectin. There w
3/29	Meta Kow et al., Pha meta-analysis The association between the use of ivermec Small meta analysis of 6 RCTs showing mortality OR 0.21 [0.11-0.42]. Authors do not include two
3/26	PrEP <i>Tanioka</i> et al., death , \$\sqrt{88.2%}\$, p Why COVID-19 is not so spread in Africa: Ho Retrospective study of the 31 onchocerciasis-endemic countries using the community-directed tre
3/25	In Sili <i>Udofia</i> et al., Network Modeling Analy In silico studies of selected multi-drug target In Silico analysis finding that ivermectin had the highest binding energy against the 3CLpro of SAR
3/25	In Sili <i>Choudhury</i> et al., Future Medicine, doi: Exploring the binding efficacy of ivermectin a <i>In Silico</i> analysis finding that ivermectin has high binding affinity for the SARS-CoV-2 viral spike pro
3/25	Late <i>Huvemek Pres</i> no improv., J31.6 Kovid-19 - Huvemek® Phase 2 clinical trial Phase 2 results from a multicenter RCT of hospitalized patients in Bulgaria showing faster viral cle
3/24	Revi <i>Yagisawa</i> et al review Global trends in clinical studies of ivermectin Review of ivermectin for COVID-19. Authors note that Kitasato University's project was expanded i
3/21	Early <i>Emmerich et al., Int. J. Environ. Res. P</i> Comparisons between the Neighboring Stat Comparison between the two largest neighboring states in Brazil, Amazonas and Pará, showing m
3/18	Late Del Franco et al., Journal of Biomedic Ivermectin in Long-Covid Patients: A Retrosp

https://c19ivermectin.com 2/11

	Retrospective 856 patients previously admitted to hospital for COVID-19 in Argentina, finding that i
3/12	Early Roy et al., med recov. time, \$\gup\$5.6 Outcome of Different Therapeutic Interventio Retrospective database analysis of 56 mild COVID-19 patients, all treated with vitamin C, vitamin D
3/11	Meta Nardelli et al., death, \downarrow 79.5%, p< Crying wolf in time of Corona: the strange ca Meta analysis of RCT mortality results showing RR 0.19, p < 0.00001.
3/11	Meta Scheim et al., meta-analysis Ivermectin sales in Valle del Cauca, Colombi Analysis of several issues with López-Medina et al. including the atypical adverse effects in the co
3/11	Meta <i>Bryant et al., R</i> death, ↓68.0%, p Ivermectin for prevention and treatment of C Systematic review and meta analysis of 21 RCTs finding mortality RR 0.32 [0.14-0.72], and prophyl
3/11	Meta <i>Scheim et al.,</i> meta-analysis Protocol violations in López-Medina et al.: 38 Report on protocol violations in López-Medina et al.
3/10	In Vit Yesilbag et al., in vitro Ivermectin also inhibits the replication of bov In Vitro study showing that ivermectin can inhibit infection of bovine respiratory disease viral agent
3/9	Late <i>Pott-Junior</i> et ventilation , \$\sqrt{85.2} Use of ivermectin in the treatment of Covid-1 Small RCT with 4 control patients and 28 ivermectin patients split across 3 different dosage levels,
3/8	Early <i>Chamie-Quintero</i> et al., <i>OSF Preprints</i> Ivermectin for COVID-19 in Peru: 14-fold red Analysis of ivermectin use in Peru concluding that ivermectin most likely caused a 14 times reduct
3/8	Late <i>Guzman et al., medRxiv, doi:10.1101/2</i> Factors associated with increased mortality Retrospective 196 critically ill patients in Mexico. Patients overlap with the existing RCT by Beltran
3/8	Late <i>Galan et al., Pathogens and Global He</i> Phase 2 randomized study on chloroquine, h RCT 168 very late stage severe condition hospitalized patients comparing CQ, HCQ, and ivermecti
3/5	Safety Descotes, J., I safety analysis Medical Safety of Ivermectin Safety analysis of >350 articles showing that ivermectin has an excellent safety profile. The author
3/4	Early López-Medina death, 166.8%, p Effect of Ivermectin on Time to Resolution o An open letter, signed by >100 physicians, concluding this study is fatally flawed can be found at [
3/1	In Sili Saha et al., Structural Chemistry, doi:1 The Binding mechanism of ivermectin and le In Silico analysis predicting that ivermectin has a large binding affinity for the SARS-CoV-2 spike pr
2/23	

https://c19ivermectin.com 3/11

	Late Gonzalez et al death, ↓14.4%, p Efficacy and safety of Ivermectin and Hydrox RCT late stage severe condition (93% SOFA ≥ 2, 96% APACHE ≥ 8) high comorbidity hospitalized p
2/20	News BIRD Meeting news BIRD Meeting 20th February 2021 The British Ivermectin Recommendation Development (BIRD) panel, with dozens of multi-national
2/16	Early <i>Elalfy</i> et al., J viral+, ↓86.9%, p< Effect of a combination of Nitazoxanide, Rib Non-randomized controlled trial with 62 mild and early moderate patients with home treatment wit
2/15	PrEP Behera et al., R cases, \$\grap\$83.0%, p Prophylactic role of ivermectin in SARS-CoV Prospective prophylaxis study with 3,532 healthcare workers, 2,199 receiving two-dose ivermectin
2/12	Early <i>Schwartz, E., I</i> hosp., \$\psi\$70.2%, p= Ivermectin vs. placebo treatment in non-hos Double blind RCT for mild-moderate COVID-19 outpatients in Israel showing significantly faster re
2/10	Late <i>Lima-Morales</i> death, ↓77.7%, p< Effectiveness of a multidrug therapy consisti Prospective trial of 768 COVID-19 outpatients in Mexico, 481 treated with ivermectin, AZ, monteluk
2/2	Early <i>Mohan</i> et al., R no recov., \62.5% Ivermectin in mild and moderate COVID-19 (RCT in India with low risk patients, comparing 24mg ivermectin, 12mg ivermectin, and placebo sh
1/29	Meta <i>Cobos-Campo</i> meta-analysis Potential use of ivermectin for the treatment Review finding that there appears to be sufficient evidence to recommend ivermectin for the treat
1/27	Meta <i>Castaneda-Sa</i> meta-analysis Outcomes of Ivermectin in the treatment of Student-written meta analysis of a very small subset of studies exhibiting very high bias and signi
1/25	In Sili <i>Eweas et al., Frontiers in Microbiology,</i> Molecular Docking Reveals Ivermectin and R Molecular docking analysis showing that ivermectin efficiently binds to the viral S protein as well a
1/23	Anim <i>Errecalde</i> et al animal study Safety and Pharmacokinetic Assessments o Animal study of a novel spray formulation of ivermectin, showing an advantage of the spray formu
1/21	Early <i>Chamie-Quintero</i> et al., <i>Preprint</i> , <i>doi:1</i> Sharp Reductions in COVID-19 Case Fatalitie Analysis of ivermectin usage within states in Peru showing sharp reductions in COVID-19 deaths c
1/20	In Vit <i>Mody et al., Co in vitro</i> Identification of 3-chymotrypsin like proteas Computational molecular modeling screening and <i>in vitro</i> analysis for inhibitory effects on SARS-C
1/19	Late <i>Shahbaznejad</i> death, ↑197.1%, Effect of ivermectin on COVID-19: A multicen RCT in Iran showing shorter time to recovery and shorter hospitalization time with ivermectin. The

https://c19ivermectin.com 4/11

1/19	Meta Hill et al., Rese death, ↓75.0%, p Meta-analysis of randomized trials of iverme Meta analysis of 18 ivermectin RCTs with 2,282 patients showing faster viral clearance (dose and
1/16	Early Raad et al., Chi hosp., \$85.7%, p= In vivo use of ivermectin (IVR) for treatment RCT in Lebanon showing significantly lower viral load at day 3, and lower hospitalization. Results a
1/16	Early <i>Bukhari</i> et al., viral+, ↓82.4%, p< Efficacy of Ivermectin in COVID-19 Patients RCT of relatively low risk hospitalized patients with 50 ivermectin and 50 control patients showing
1/13	Early, Kory et al., Fro review Review of the Emerging Evidence Demonstr Meta analysis of ivermectin clinical studies and natural experiments where ivermectin has been wi
1/12	Late <i>Okumuş</i> et al., death , \\ 33.3% , p Evaluation of the Effectiveness and Safety of Small RCT for severe COVID-19 comparing the addition of ivermectin to SOC (low dose HCQ+AZ+f
1/11	PrEP <i>Chahla</i> et al., cases, \$\geq 95.2%, p A randomized trial - intensive treatment base Prophylaxis RCT for ivermectin and iota-carrageenan in Argentina, 117 healthcare workers treated
1/11	N/A <i>Bousquet-Mel</i> dosing study Large Impact of obesity on the disposition of Animal dosing study with an obese dog model concluding that ivermectin maintenance doses sho
1/10	Revi Formiga et al., review Ivermectin: an award-winning drug with expe Review hypothesizing that micro- and nanotechnology-based formulations of ivermectin for the p
1/9	Early <i>Kirti et al., med</i> death, ↓88.7%, p Ivermectin as a potential treatment for mild t RCT with 112 mild and moderate COVID-19 patients in India, showing lower mortality, ventilation,
1/8	Early <i>Chamie, J. (Ne</i> news COVID-19 in Mexico Comparison of COVID-19 death rates in Mexico showing that the only state using ivermectin has a
1/6	Early Babalola et al., viral+, \\$63.9%, p= Ivermectin shows clinical benefits in mild to Small RCT comparing ivermectin 6mg & 12mg q84hr with lopinavir/ritonavir, showing a statisticall
1/6	PrEP <i>Hirsch</i> et al., <i>Microbiology</i> & <i>Infectious</i> Ivermectin as Prophylaxis Against COVID-19 Report on ivermectin prophylaxis for healthcare workers in a hospital in Argentina, showing 0 case
1/3	Early, Lawrie et al., P death, \$\183.0\%, p< Ivermectin reduces the risk of death from C Meta analysis confirming the effectiveness of ivermectin for COVID-19, showing ivermectin treatm
12/31	Late Wijaya et al., Cermin Dunia Kedoktera Ivermectin as a Potential Therapeutic Agent Case report on 3 confirmed cases of COVID-19 with significant clinical and radiological improvem

https://c19ivermectin.com 5/11

12/31	Anim <i>Madrid</i> et al., H animal study Safety of oral administration of high doses o <i>In vivo</i> analysis of the safety of high dose ivermectin with a Corydoras fish animal model.
12/30	Revi <i>McCullough et</i> review Multifaceted highly targeted sequential multi Review urging early treatment of COVID-19 with sequential multidrug treatment that has been sho
12/30	Early <i>Procter et al., Reviews in Cardiovascul</i> Clinical outcomes after early ambulatory mu Retrospective 922 outpatients, with 320 treated early due to age>50 or comorbidities, showing 2.2
12/27	Meta <i>Hill, A., Preprin</i> meta-analysis Meta-analysis of clinical trials of ivermectin t WHO-funded meta analysis showing ivermectin treatment mortality relative risk RR 0.17 [0.08-0.3
12/24	In Vit Jeffreys et al., in vitro Remdesivir-Ivermectin combination displays In Vitro study showing enhanced antiviral activity of ivermectin and remdesivir in combination.
12/20	PrEP Vallejos et al., cases, \$\psi\$73.4%, p Ivermectin to prevent hospitalizations in pati Report on ivermectin prophylaxis in a hospital in Argentina showing lower cases for healthcare wo
12/18	Early, Kory et al., FLC death, \ 69.0%, p< Review of the Emerging Evidence Demonstr Meta analysis of ivermectin clinical studies and natural experiments where ivermectin has been wi
12/15	PrEP Alam et al., Eur cases, \$\gup\90.6\%, p Ivermectin as Pre-exposure Prophylaxis for 91\% reduction in COVID-19 cases with ivermectin prophylaxis. 118 healthcare workers in Banglad
12/15	Early Afsar et al., SS symptoms, 192.2 Ivermectin Use Associated with Reduced Du Small 95 patient study in Pakistan adding ivermectin to standard of care (HCQ+AZ) for outpatients
12/11	Early <i>Hussain</i> et al., <i>International Journal of</i> Outcome of ivermectin and doxycycline in ca Small case study of ivermectin + doxycycline with 8 cancer patients, with all patients becoming P
12/7	Early <i>Chaccour</i> et al symp. prob., \$\pm\$52 The effect of early treatment with ivermectin Tiny RCT for early treatment of mild COVID-19 in low risk patients, with 12 400mcg/kg single dose
12/4	Meta <i>Kalfas et al., m</i> meta-analysis The therapeutic potential of ivermectin for C Review of ivermectin mechanisms and 8 trials, showing positive mortality benefit, reduced time to
12/4	In Vit Surnar et al., A in vitro Clinically Approved Antiviral Drug in an Orally In Vitro analysis of ivermectin with orally administrable nanoparticles showing efficacy for decreas
12/2	Early Ahmed et al., I symptoms, \$\gs\$85.0 A five day course of ivermectin for the treat Small 72 patient RCT of ivermectin and ivermectin + doxycycline showing faster recovery with iver

https://c19ivermectin.com 6/11

12/2	Early <i>Chamie, J. (Ne</i> news The effect of using ivermectin to control CO After starting to distribute ivermectin in drug kits in July, the Mexican state of Chiapas has seen a
12/1	Early Alonso et al., (death, \$\psi 91.8\%, p COVID-19: Uso de ivermectina Observational study in Argentina showing significantly lower mortality in the 60 days after adoptin
11/28	PrEP Bernigaud et al death, \$\psi 99.4\%, p Ivermectin benefit: from scabies to COVID-1 69 residents of a French care home, median age 90, were treated with ivermectin for a scabies out
11/28	PrEP <i>Hellwig et al., I.</i> cases, \$\psi\$78.0%, p A COVID-19 Prophylaxis? Lower incidence as Analysis of COVID-19 cases vs. widespread prophylactic use of ivermectin for parasitic infections
11/24	Late <i>Niaee et al., Re</i> death, \\$1.8%, p Ivermectin as an adjunct treatment for hospi 82% lower mortality with ivermectin. RCT with 180 hospitalized patients showing reduced mortalit
11/22	Anim de Melo et al., animal study Anti-COVID-19 efficacy of ivermectin in the g Hamster study finding significantly lower COVID-19 pathology although not finding lower viral load
11/18	Late <i>Budhiraja</i> et al death, \$\psi 99.1\%, p Clinical Profile of First 1000 COVID-19 Cases Retrospective 976 hospitalized patients with 34 treated with ivermectin showing ivermectin mortal
11/17	PrEP Carvallo et al., cases, \$\geq 99.9\%, p Study of the Efficacy and Safety of Topical Iv Prophylaxis study using ivermectin and iota-carrageenan showing 0 of 788 cases from treated he
11/14	Late <i>Spoorthi</i> et al., recov. time, \$\geq 21 Utility of Ivermectin and Doxycycline combin 100 patient prospective trial of ivermectin + doxycycline showing reduced time to symptom resolu
11/13	PrEP <i>Elgazzar</i> et al., cases, \$\pm\$80.0%, p Efficacy and Safety of Ivermectin for Treatm RCT for prophylaxis with ivermectin showing a significant reduction in cases with treatment. Relat
11/13	Late <i>Elgazzar</i> et al., death, \$\psi 91.7\%, p< Efficacy and Safety of Ivermectin for Treatm RCT comparing ivermectin + SOC vs. HCQ + SOC, showing a significant reduction in mortality with
11/11	Late <i>Camprubí</i> et al ventilation , ↓ 40.0 Lack of efficacy of standard doses of iverme Tiny 26 patients retrospective study of ivermectin 200 μg/kg, median 12 days after symptoms, not
11/11	Early Krolewiecki et al., SSRN (Preprint) Antiviral Effect of High-Dose Ivermectin in A Viral load RCT finding a concentration dependent antiviral activity of oral high dose ivermectin at a
11/10	Revi <i>Turkia, M., Res</i> review FLCCC Alliance MATH+ ascorbic acid and I Review suggesting that ivermectin should be used based on existing data suggesting significant b

https://c19ivermectin.com 7/11

11/4	Early <i>Cadegiani</i> et al death , 178.3% , p Early COVID-19 Therapy with Azithromycin P Comparison of HCQ, nitazoxanide, and ivermectin showing similar effectiveness for overall clinical
11/3	Early, <i>Morgenstern</i> et al., J. Clinical Trials (pr The Use of Compassionate Ivermectin in the Retrospective 3,099 outpatients treated with ivermectin in an ER. Of 2,706 treated on an outpatien
11/3	PrEP Behera et al., P cases, \$\gs\$53.8%, p Role of ivermectin in the prevention of SARS Retrospective matched case-control prophylaxis study for HCQ, ivermectin, and vitamin C with 37
11/2	Anim <i>Arévalo et al.,</i> animal study Ivermectin reduces in vivo coronavirus infect Mouse study showing ivermectin reducing MHV viral load and disease. MHV is a type 2 family RN
10/31	PrEP Chang et al., ResearchGate (Preprint) COVID-19: Effectiveness of pre-exposure pro Pre-exposure prophylaxis study with 129 people split into high/low exposure groups, with each gro
10/31	Early Szente Fonsec hosp., †13.9%, p= Risk of Hospitalization for Covid-19 Outpatie Retrospective 717 patients in Brazil showing OR 1.17 [0.72-1.90] for ivermectin. With significant ov
10/26	Late <i>Hashim et al.</i> , death , \(\delta 66.7%, p Controlled randomized clinical trial on using RCT 70 ivermectin+doxycycline patients and 70 control patients showing reduced time to recover
10/22	PrEP Guerrero et al., Colombia Médica, doi: COVID-19: The Ivermectin African Enigma Study of African Programme for Onchocerciasis Control (APOC) countries, which used ivermectin,
10/19	PrEP Carvallo et al., cases, \$\gup\$96.3%, p Usefulness of Topic Ivermectin and Carrage Prophylaxis study using ivermectin and carrageenan showing 0 of 131 cases from treated healthc
10/13	Early <i>Chaccour et al</i> animal study Nebulized ivermectin for COVID-19 and othe Study showing that nebulized ivermectin can reach pharmacodynamic concentrations in the lung
10/13	Late Rajter et al., Ch death, ↓46.0%, p Use of Ivermectin is Associated with Lower Retrospective 280 hospitalized patients showing lower mortality with ivermectin (13.3% vs 24.5%),
10/9	Early <i>Mahmud</i> et al., death, \$\grapsilon 85.7%, p Ivermectin in combination with doxycycline f RCT for ivermectin+doxycycline showing improvements in mortality, recovery, progression, and vir
10/8	Theo Francés-Mone theory Has Ivermectin Virus-Directed Effects agains In silico study showing that ivermectin is capable of interfering in different key steps of the SARS
10/8	Late Soto-Becerra e death, ↓17.1%, p Real-World Effectiveness of hydroxychloroqu

https://c19ivermectin.com

	Retrospective database study of 5683 patients, 692 received HCQ/CQ+AZ, 200 received HCQ/CQ,
9/30	Late <i>Chachar et al.,</i> no recov., \10.0% Effectiveness of Ivermectin in SARS-CoV-2/ Small RCT with 25 ivermectin and 25 control patients, not finding a significant difference in recove
9/24	Late <i>Khan et al., Arc</i> death, ↓87.0%, p< Ivermectin treatment may improve the progn Retrospective 115 ivermectin patients and 133 control patients showing significantly lower death
9/22	In Vit Li et al., J. Cell in vitro Quantitative proteomics reveals a broad-spe In Vitro study showing Ivermectin is a safe wide-spectrum antiviral against SARS-CoV-2, human pa
9/15	Early <i>Carvallo et al.,</i> death, \$\pm\$ 87.9%, p Safety and Efficacy of the combined use of i Prospective trial of ivermectin, dexamethasone, enoxaparin, and aspirin. There was one death fro
9/15	Revi Jans et al., Cell review Ivermectin as a Broad-Spectrum Host-Direct Review of ivermectin as a host-directed broad-spectrum antiviral agent for a range of viruses, inclu
9/6	Revi <i>DiNicolantonio</i> review Ivermectin may be a clinically useful anti-infl Review suggesting that ivermectin may be useful for late stage COVID-19. Authors note that iverm
9/3	Late <i>Podder</i> et al., I recov. time, \$\pm\$16 Outcome of ivermectin treated mild to mode Small RCT with 32 ivermectin patients and 30 control patients. The mean recovery time after enrol
8/31	Late <i>Kishoria</i> et al., no disch., †7.5%, Ivermectin as adjuvant to hydroxychloroquin Small RCT of hospitalized patients in India with 19 ivermectin patients and 13 control patients, wit
8/28	PrEP Shouman et al symp. case, \$\gup\$91 Use of Ivermectin as a Potential Chemoprop PEP trial for asymptomatic close contacts of COVID-19 patients, 203 ivermectin patients and 101
8/15	Early <i>Espitia-Hernan</i> viral+, \$\psi\$97.2%, p< Effects of Ivermectin-azithromycin-cholecalc Small study with 28 patients treated with ivermectin + AZ + cholecalciferol and 7 control patients
8/14	Late <i>Bhattacharya</i> et al., Int. J. Scientific Re Observational Study on Clinical Features, Tre Retrospective 148 hospitalized patients showing triple therapy with ivermectin + atorvastatin + N
7/31	Revi <i>Vora et al., Indi</i> review White paper on Ivermectin as a potential the Panel review of ivermectin reporting that "ivermectin in the dose of 12mg BD alone or in combinati
7/31	Late <i>Chang et al., ResearchGate (Preprint)</i> Post-acute or prolonged COVID-19: ivermecti Report on 33 patients with persistent or post-acute symptoms treated with ivermectin, showing a
7/31	

https://c19ivermectin.com 9/11

	Theo Proposed	Chang et al., R I PEP protocol based	theory d on ivermectin.	COVID-19: Post-exposure prophylaxis with iv
7/31	Late Case stud		of Bangladesh Col eated with ivermectin a	A Case Series of 100 COVID-19 Positive Pati nd doxycycline, with no ICU admission, death
7/31	Late Comparis		angladesh Coll. Phy reated with ivermectin	Comparison of Viral Clearance between Iver + doxycycline and 200 treated with HCQ + AZ
7/14	Early Small 116	Chowdhury et 5 patient RCT with lo	hosp., ↓80.6%, p= ow-risk patients compar	A Comparative Study on Ivermectin-Doxycyc ring ivermectin+doxycycline and HCQ+AZ, sho
7/8	Late Small tria	Gorial et al., m I of hospitalized pati	death, ↓71.0%, p ients with 16 of 87 patio	Effectiveness of Ivermectin as add-on Thera ents being treated with ivermectin showing a
6/19	Theo In silico a	Lehrer et al., In nalysis showing iver	theory mectin docking which i	Ivermectin Docks to the SARS-CoV-2 Spike R may interfere with the attachment of the spike
6/16	Early Prospecti	Ramos et al., Preprive study of 63 outpa	, , ,	Intervención de la Ivermectina Pre-Hospitala vith ivermectin, reporting significant improve
6/12	Revi Review of	Heidary et al., f the antimicrobial, a	review ntiviral, and anti-cancer	Ivermectin: a systematic review from antivira properties of ivermectin. Antiviral effects hav
5/2	Early Peru obse	_	h Gate, doi:10.1314 y of 7 patients treated v	Inclusión de la ivermectina en la primera líne vith ivermectin, showing improvement and re
4/21	Revi Response	Bray et al., Anti es to Caly et al., and	review the author's reply. The o	Ivermectin and COVID-19: A report in Antivira original authors note that "ivermectin's key dir
4/3	In Vit In Vitro st	Caly et al., Anti udy showing that ive	in vitro ermectin is an inhibitor	The FDA-approved drug ivermectin inhibits t of SARS-CoV-2, with a single addition to Vero
2013	N/A Safety stu	Guzzo et al., J udy concluding that	safety analysis ivermectin was general	Safety, Tolerability, and Pharmacokinetics of ly well tolerated, with no indication of associat

For search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), PRISMA answers, and statistical methods see ivmmeta.com. In Vitro, Ex Vivo, Meta, Theory, Safety, Review, and News items are not included in the study count. There is a total of 134 items. Studies with preprints and journal versions are listed under the earlier preprint date.

https://c19ivermectin.com 10/11

https://c19ivermectin.com